合生元改变非酒精性脂肪肝患者粪便微生物组,但不减少肝脏脂肪或纤维化:一项随机试验
该双盲2期试验纳入104例非酒精性脂肪肝(NAFLD)患者,随机接受合生元(低聚果糖4g每日两次联合动物双歧杆菌乳亚种BB-12)或安慰剂治疗10-14个月。结果显示合生元改变了粪便微生物组,但肝脏脂肪含量和纤维化标志物与安慰剂组无显著差异,仅体重减轻与肝脏脂肪显著减少相关。
要点
- 合生元组粪便双歧杆菌和粪杆菌比例升高,另两种菌减少,安慰剂组无此变化。
核心结论
- 在NAFLD患者中,为期约1年的合生元治疗改变了粪便微生物组,但未减少肝脏脂肪含量或纤维化标志物。
研究设计与样本
- 双盲2期随机对照试验,纳入英国104例NAFLD患者,平均年龄50.8±12.6岁,65%为男性,37%患糖尿病。
- 参与者随机接受合生元(低聚果糖4g每日两次联合动物双歧杆菌乳亚种BB-12,n=55)或安慰剂(n=49)治疗10-14个月。
- 通过磁共振波谱测定肝脏脂肪含量,用验证性生物标志物评分和振动控制瞬时弹性成像评估肝纤维化,粪便微生物组用16S rDNA测序分析。
主要发现
- 合生元组基线及研究结束时磁共振波谱肝脏脂肪百分比分别为32.3%±24.8%和28.5%±20.1%,安慰剂组分别为31.3%±22%和25.2%±17.2%。
- 合生元组粪便中双歧杆菌和粪杆菌比例较基线升高,Oscillibacter和Alistipes比例降低,安慰剂组无这些变化。
- 粪便微生物组成变化与肝脏脂肪或纤维化标志物无关。
临床怎么用
- 不推荐使用合生元作为NAFLD患者减少肝脏脂肪或改善纤维化的治疗手段。
- 体重减轻仍是与肝脏脂肪减少显著相关的因素,应作为NAFLD管理的重点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Dysbiosis of the intestinal microbiota has been associated with nonalcoholic fatty liver disease (NAFLD). We investigated whether administration of a synbiotic combination of probiotic and prebiotic agents affected liver fat content, biomarkers of liver fibrosis, and the composition of the fecal microbiome in patients with NAFLD. METHODS: We performed a double-blind phase 2 trial of 104 patients with NAFLD in the United Kingdom. Participants (mean age, 50.8 ± 12.6 years; 65% men; 37% with diabetes) were randomly assigned to groups given the synbiotic agents (fructo-oligosaccharides, 4 g twice per day, plus Bifidobacterium animalis subspecies lactis BB-12; n = 55) or placebo (n = 49) for 10-14 months. Liver fat content was measured at the start and end of the study by magnetic resonance spectroscopy, and liver fibrosis was determined from a validated biomarker scoring system and vibration-controlled transient elastography. Fecal samples were collected at the start and end of the study, the fecal microbiome were analyzed by 16S ribosomal DNA sequencing. RESULTS: Mean baseline and end-of-study magnetic resonance spectroscopy liver fat percentage values were 32.3% ± 24.8% and 28.5% ± 20.1% in the synbiotic group and 31.3% ± 22% and 25.2% ± 17.2% in the placebo group. In the unadjusted intention-to-treat analysis, we found no significant difference in liver fat reduction between groups (β = 2.8; 95% confidence interval, -2.2 to 7.8; P = .30). In a fully adjusted regression model (adjusted for baseline measurement of the outcome plus age, sex, weight difference, and baseline weight), only weight loss was associated with a significant decrease in liver fat (β = 2; 95% confidence interval, 1.5-2.6; P = .03). Fecal samples from patients who received the synbiotic had higher proportions of Bifidobacterium and Faecalibacterium species, and reductions in Oscillibacter and Alistipes species, compared with baseline; these changes were not observed in the placebo group. Changes in the composition of fecal microbiota were not associated with liver fat or markers of fibrosis. CONCLUSIONS: In a randomized trial of patients with NAFLD, 1 year of administration of a synbiotic combination (probiotic and prebiotic) altered the fecal microbiome but did not reduce liver fat content or markers of liver fibrosis. (ClinicalTrials.gov, Number: NCT01680640).
引用
- Scorletti E, Afolabi PR, Miles EA, et al. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2020. PMID: 31987796. doi:10.1053/j.gastro.2020.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。